CXCL10 and metastatic melanoma: The response to immunotherapy and immune cell infiltration were correlated with CXCL10 expression in metastatic melanoma patients [22,23], which suggests that CXCL10 is a strong biomarker for a favorable prognosis with immune checkpoint inhibitor (ICI) therapy.